The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results
Abstract
In a 6-month, placebo-controlled trial, oral fingolimod (FTY720) 1.25 or 5.0 mg, once daily, significantly reduced MRI inflammatory activity and annualized relapse rate compared with placebo in patients with relapsing multiple sclerosis (MS). The objectives were to monitor the 36-month, interim efficacy and safety results of the ongoing extension of this study. In the extension (months 7—36), placebo-treated patients were re-randomized to either dose of fingolimod; fingolimod-treated patients continued at the same dose. During months 15—24, all patients receiving fingolimod 5.0 mg switched to 1.25 mg. Of the 250 patients who entered the extension study, 173 (69%) continued to month 36. Most patients were free from gadolinium-enhanced lesions (88—89%) or new T2 lesions (70—78%) at month 36. Patients receiving continuous fingolimod treatment had sustained low annualized relapse rates of 0.20—0.21, and 68—73% remained relapse-free at month 36. Over 36 months, nasopharyngitis (34%), headache (30%), fatigue (19%) and influenza (18%) were the most commonly reported adverse events. Pulmonary function remained stable and blood pressure was stable after an initial increase (3—5 mmHg) during the first 6 months of fingolimod treatment; serious adverse events included infections and skin cancer. The low MRI and clinical disease activity at 6 months were maintained at 36 months with fingolimod, which was generally well tolerated by most patients. The efficacy and safety of oral fingolimod are being further evaluated in a large phase III MS study programme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., & Cyster, J. G. (2004) · Nature · doi:10.1038/nature02284 · Cited by 2,581
Wheeler, D., Bandaru, V. V. R., Calabresi, P. A., Nath, A., & Haughey, N. J. (2008) · Brain · doi:10.1093/brain/awn190 · Cited by 171
Cited by
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
Self-citationFingolimod for Multiple Sclerosis
Pelletier, D., & Hafler, D. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmct1101691 · Cited by 315
Patejdl, R., Penner, I. K., Noack, T. K., & Zettl, U. K. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.11.005 · Cited by 141
Glial cells as therapeutic targets in progressive multiple sclerosis
Wilbanks, B., Maher, L., & Rodriguez, M. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1614443 · Cited by 17
Metadata
- Authors
- Comi, G., O'Connor, P., Montalban, X., Antel, J., Radue, E.-W., Karlsson, G., Pohlmann, H., Aradhye, S., Kappos, L., & FTY720D2201 Study Group
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2009-12-22
- Volume
- 16
- Issue
- 2
- Pages
- 197-207
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W2135746117
- Cited by
- 158
- References
- 2
- FWCI
- 11.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. https://app.cochat.ai/papers/10.1177/1352458509357065
- The paper
- Comi, G., O'Connor, P., Montalban, X., Antel, J., Radue, E.-W., Karlsson, G., Pohlmann, H., Aradhye, S., Kappos, L., & FTY720D2201 Study Group. (2010). Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458509357065
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.